ClinicalTrials.gg
CompletedNCT05113641ReDACKDUpdated Oct 23, 2026

Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD)

An interventional study of Alkalizing Fruit and Vegetables and Sodium bicarbonate in Chronic Kidney Diseases and Metabolic Acidosis, sponsored by Dylan MacKay. Completed at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Dylan MacKay · Not applicable, Interventional, and Treatment

How we know

Updated Oct 23, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 215 studies in Renal Insufficiency, Chronic with a site in Canada — 37 open to participants now, 61 under way, 16 of them phase 3. Renal Insufficiency, Chronic · Canada.

Enrollment
146th of 173
37 · median 195
Started
2023
with 9 others
No phase
62 of 215
13 open now
Registered
141st of 215
by date

Among the 215 studies in Renal Insufficiency, Chronic with a site in Canada, this one is the 146th largest by enrollment of the 173 interventional ones that give a count, is one of 10 that started in 2023, is one of 62 with no phase, and was the 141st registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

37 of the 215 studies in Renal Insufficiency, Chronic with a site in Canada are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 215 studies in Renal Insufficiency, Chronic with a site in Canada, or all of them as a file.
02

Study summary

Metabolic acidosis is a common problem that occurs with worsening chronic kidney disease. Dietary acid can build up when the kidneys are not working well. This can be associated with a higher risk of worsening kidney function and death. The usual treatment is a medication called sodium bicarbonate which works to balance the acids in the body. The medication however often does not work and causes side effects. Consumption of alkalizing fruit and vegetables may work as a treatment for metabolic acidosis. This trial is being done to see if fruit and vegetables, provided via home delivery, can become a viable management for metabolic acidosis in patients with chronic kidney disease.

Read the detailed description

Metabolic acidosis is a common complication of advanced chronic kidney disease (CKD). As kidney function declines, the ability to excrete excess dietary acid is reduced. This can lead to the development of metabolic acidosis, an imbalance in the body's acid-base balance. Metabolic acidosis is associated with a higher risk of CKD progression and mortality. Typical treatment includes an oral alkali, such as sodium citrate or sodium bicarbonate. Recent studies have shown that the treatment of metabolic acidosis can reduce the decline in kidney function and potentially prevent progression of CKD to dialysis. Treatment rates with an oral alkali are low because the treatments are ineffective, often poorly tolerated, and may be associated with net harm. Base producing fruit and vegetables are a potential treatment of metabolic acidosis by reducing the dietary contribution to overall acid load that must be managed by the kidneys. A recent systematic review and meta-analysis of clinical trials using oral alkali supplements or reduction in dietary acid intake using fruits and vegetables, when compared to no treatment, usual care or placebo found that these treatments increased serum bicarbonate and slowed the decline of kidney function. Fruit and vegetables are an effective and well-tolerated therapy for the treatment of metabolic acidosis in CKD. While oral alkali therapy has known adverse effects, important limitations also exist in the widespread applicability of fruit and vegetables as a treatment for metabolic acidosis. Only 2 single center randomized trials have examined the efficacy of fruit and vegetables for the management for acidosis. This dual-center trial will be the first randomized trial in Canada to evaluate the feasibility of providing fruit and vegetables via home delivery to patients for the management of metabolic acidosis in CKD. This study will be critical in designing a pan-Canadian phase 3 trial testing the efficacy of alkalizing fruit and vegetable provision on slowing the progression of CKD.

03

Conditions studied

  • Chronic Kidney Diseases
  • Metabolic Acidosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to give for participation in the trial
  • Male or Female, aged 18 years or above
  • Participants who have an between 15 and 40 ml/min/1.73m2
  • Two consecutive measurements of serum bicarbonate of 14 to 22 mEq/L
  • Systolic and diastolic blood pressure \<160/100 mmHg
  • Serum potassium \<5.3 mmol/L
  • below ≤ 11%
  • Are registered in the nephrology clinic in Winnipeg or Halifax
  • Participants are able to communicate in English and provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Anuria, dialysis or acute kidney injury/acute kidney failure in the 3 months prior to screening
  • that requires the participant to be on oxygen
  • Class 3-4 Heart failure symptoms or heart, liver or renal transplant
  • A myocardial infarction or stroke within the last 6 months
  • Unable to consume study treatments or control, such as swallowing or GI issues
  • Participants who have participated in another research trial involving an product in the past 12 weeks
  • Currently on potassium binding therapy
  • Female participant who is pregnant or on lactating
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Alkalizing Fruit and Vegetables

    Participants randomized to fruit and vegetables (F+V) will receive weekly supplementation of alkalizing fruits and vegetables via home delivery in a box format. Participants will receive a 1-hour dietary counseling session from a registered dietitian (RD), following randomization, either in person or via videoconference, depending on regional coronavirus disease (COVID) 19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the F+V into the participant's current diet. Intervention will last 12 months.

    Dietary Supplement: Alkalizing Fruit and Vegetables

  • Active comparator
    Sodium Bicarbonate

    Participants randomized to the alkali therapy will receive oral sodium bicarbonate 500mg tablets three times a day, reflecting a common starting dose at clinical practice. Thereafter, decisions around dose titration for the sodium bicarbonate will then be transferred to the participant's nephrologist who will be responsible for monitoring the participants serum bicarbonate concentration with a goal of maintaining a serum bicarbonate level \>22 mEq/L. Participants will receive counselling from a registered dietician (RD) as part of the standard care. Intervention will last 12 months.

    Drug: Sodium bicarbonate

Interventions

  • Dietary supplementAlkalizing Fruit and Vegetables

    The weekly deliveries will contain combinations of fresh, frozen, and dried fruits and vegetables, as well as juices and soups which have been selected for their negative potential renal acid load (PRAL) values and shelf-life. All participants will be started at a F+V intake equal to -30 to -40 mEq per day reduction in dietary acid load estimated by the PRAL equation. Participants serum bicarbonate concentration will be measured at 1 month, and at 3 months, those with values \< 22 mEq/L will have their recommended amount of F+V increased to -40 to -50 mEq per day. If a participant's 1- or 3-month serum bicarbonate value exceeds 29 mEq/L, their target dose of F+V in mEq/d will be reduced by 25%.

  • Study nephrologist will prescribe the oral alkali therapy (sodium bicarbonate) and the medications will be dispensed by the dispensed by the clinic/hospital pharmacies.

06

What researchers measure

Primary outcomes

  1. Randomization to preliminary eligible ratio

    Ratio of randomized to preliminary eligible greater, calculated among all patients approached to participate expressed as percentage will be collected at 12 months to investigate fruit and vegetable intervention feasibility. A red, yellow, green framework has been developed as a feasibility metric: green for ratios more than 50%, yellow for ratios 20%-49.9%, and red for ratios less than 20%

    Time frame: 12 months

  2. Weekly recruitment rate

    Number of new participants per weeks of active recruitment. A green, yellow, red feasibility framework has been developed as a feasibility metric: green for ≥ 0.5 , yellow for 0.125-0.49 and red for \< 0.125

    Time frame: 12 months

  3. Study outcome follow up

    Study outcome follow up expressed as a percentage, will be calculated at 12 months to investigate the fruit and vegetable intervention feasibility. A red, yellow, green feasibility framework has been developed as a feasibility metric: green for ≥ 95% , yellow for 80%-94.9% and red for \<80%.

    Time frame: 12 months

  4. Potential renal acid load (PRAL) in mEq/day

    Calculated from average dietary intake assessed by Automated Self-Administered 24-hour Canada (ASA24) dietary recall survey conducted over three days. a red, yellow, green feasibility framework has been developed as a feasibility metric: green for \> 75% , yellow for 50%-75% and red for \<50%.

    Time frame: Baseline, 6, and 12 months

Secondary outcomes

  1. Five repetition chair stand time

    the amount of time it takes for a participant to get up out of a chair five times measured in seconds

    Time frame: Baseline, 3, 6, 9, and 12 months

  2. Physical function related quality of life

    Participants will complete the SF-12 physical component score of the Kidney Disease Quality of Life Short Form (KDQOL-SF) questionnaire. The questionnaire is scored between 0-100 with higher values representing physical function related quality of life.

    Time frame: Baseline, 3, 6, 9, and 12 months

  3. Serum bicarbonate (total CO2)

    Serum bicarbonate concentration in milliequivalents per liter (mEq/L)

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  4. Albumin

    blood albumin is measured in grams per deciliter (g/dL)

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  5. Calcium

    Total blood calcium concentration in mmol/L

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  6. Estimated Glomerular Filtration Rate (eGFR)

    calculated from serum creatinine, sex, and age, reported in mL/min/1.73 m2

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  7. Glucose

    Total blood glucose concentration in mmol/L

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  8. Potassium

    The total blood potassium concentration in mmol/L

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  9. Chloride

    Total blood chloride concentration in mmol/L

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  10. Sodium

    The total sodium concentration in mmol/L

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  11. Phosphorus

    The total blood phosphorus concentration in mmol/L

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  12. Hemoglobin A1c

    Hemoglobin A1c in percentage

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  13. Blood Urea Nitrogen (BUN)

    Blood Urea Nitrogen (BUN) is reported in millimole per litre (mmol/L)

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  14. Urine Albumin/Creatinine Ratio

    The ratio of albumin to creatinine concentrations in urine, reported in Milligrams albumin per millimole creatinine

    Time frame: Baseline, 1, 3, 6, 9, and 12 month(s)

  15. Changes in medication

    Research coordinator will update information on concomitant medications or supplements information with the participant

    Time frame: Baseline,1, 3, 6, 9, and 12 months

  16. Systolic blood pressure in mmHg

    Blood pressure will be measured in triplicate using a validated blood pressure monitor following Kidney Disease: Improving Global Outcomes (KDIGO) 2021 measurement guidelines, the average of the 2nd and 3rd measurements will be recorded.

    Time frame: Baseline, 1, 3, 6, 9, and 12 months

  17. Diastolic blood pressure in mmHg

    Blood pressure will be measured in triplicate using a validated blood pressure monitor following KDIGO 2021 measurement guidelines, the average of the 2nd and 3rd measurements will be recorded.

    Time frame: Baseline, 1, 3, 6, 9, and 12 months

  18. Edmonton Symptom Assessment System (ESAS) - Revised Renal

    A questionnaire used to rate the intensity of nine common symptoms experienced by renal patients, including pain, tiredness, drowsiness, nausea, appetite levels, shortness of breath, depression and anxiety levels, and well-being. Minimum value 0 and maximum value 100 with higher values being worse.

    Time frame: Baseline, 3, 6, 9, and 12 months

  19. All cause hospitalization

    Information on recent hospitalizations from participant's clinical records will be collected.

    Time frame: 3, 6, 9, and 12 months

  20. All cause mortality

    Information on mortality from participant's clinical records will be collected.

    Time frame: 3, 6, 9, 12 months

  21. Height

    Height will be measured using a validated stadiometer in centimeters..

    Time frame: Baseline, 3, 6, 9, and 12 months

  22. Weight

    Weight will be measured using a calibrated scale in kilograms.

    Time frame: Baseline, 3, 6, 9, and 12 months

  23. Body Mass Index (BMI)

    MBI will be calculated through dividing weight in kilograms (kg) by the square of height in meters (m2).

    Time frame: Baseline, 3, 6, 9, and 12 months

Other outcomes

  1. Exit Interviews

    Upon the completion of the 12 months of study, the participants will be invited to participate in an exit interview. This interview will involve a few open ended question and its goal is to better understand participants' personal experiences and perspectives of the study and the intervention they received, as well as their overall viewpoints of trials such as ReDACKD, as a person living with CKD and metabolic acidosis. We will offer the interview to all of the participants at the final visit of the trial; however, taking part is this interview is voluntary. The "Exit Interview Consent Form" will be used to explain the aims and procedures of the interview

    Time frame: Final Visit (Month 12)-After the completion of the trial

07

Study locations

2 sites
  • Seven Oaks General Hospital Chronic Disease Innovation Centre
    Winnipeg, Manitoba R2V 3M3, Canada
  • Chronic Kidney Disease (Renal) ClinicQEII - Dickson Building
    Halifax, Nova Scotia B3H 2Y9, Canada
08

References and documents

Publications

  • Mollard R, Cachero K, Luhovyy B, Martin H, Moisiuk S, Mahboobi S, Balshaw R, Collister D, Cahill L, Tennankore KK, Tangri N, MacKay D. Reducing Dietary Acid With Fruit and Vegetables Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD): A Clinical Research Protocol. Can J Kidney Health Dis. 2023 Aug 7;10:20543581231190180. doi: 10.1177/20543581231190180. eCollection 2023. PubMed 37560749 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Sep 2026, 37 months.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 37 months is above that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Nov 9, 2021
StartActual
Aug 4, 2023
Primary completionActual
Sep 24, 2026
CompletionActual
Sep 24, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05113641
Lead sponsor
Dylan MacKay
Collaborators
Dalhousie University, Mount Saint Vincent University
Responsible party
Dylan MacKay (Assistant Professor, University of Manitoba) — Sponsor-investigator
First posted
Nov 9, 2021
Start date
Aug 4, 2023
Primary completion
Sep 24, 2026
Completion
Sep 24, 2026
Last update
Oct 23, 2026

Study contacts

Navdeep Tangri, MD, PhD
principal investigator · Seven Oaks General Hospital Chronic Disease Innovation Centre
Dylan MacKay, PhD
principal investigator · George and Fay Yee Centre for Healthcare Innovation
Karthik Tennankore, MD
principal investigator · Nova Scotia Health Authority

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion